Scisparc announces pricing of $10 million private placement priced at-the-market

Tel aviv, israel, may 27, 2022 (globe newswire) -- scisparc ltd. (nasdaq: sprc) (the "company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that it entered into a securities purchase agreement with a single healthcare-focused institutional investor for aggregate gross proceeds of approximately $10 million, before deducting fees to the placement agent and other offering expenses payable by the company.
SPRC Ratings Summary
SPRC Quant Ranking